
Jinesh Gheeya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4907461/publications.pdf Version: 2024-02-01



LINESH CHEEVA

| # | Article | IF | CITATIONS |
|---|---|-----|-----------|
| 1 | Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. Scientific Reports, 2017, 7, 5568. | 3.3 | 37 |
| 2 | Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor. Cancer Letters, 2010, 293, 124-131. | 7.2 | 30 |
| 3 | Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage. Scientific Reports, 2017, 7, 16613. | 3.3 | 28 |
| 4 | Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267. | 3.0 | 28 |
| 5 | Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7337-7340. | 2.2 | 26 |
| 6 | Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biology and Therapy, 2009, 8, 2386-2395. | 3.4 | 25 |
| 7 | Development of Peptide Nucleic Acid Probes for Detection of the HER2 Oncogene. PLoS ONE, 2013, 8, e58870. | 2.5 | 19 |
| 8 | Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, 2018, 2018, 1-15. | 3.0 | 16 |
| 9 | 715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC). Annals of Oncology, 2020, 31, S562-S563. | 1.2 | 0 |